– Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small cell lung cancer (NSCLC)
– First safety data presented from combination study of PRT3789 and docetaxel demonstrated an acceptable safety profile
Read more at globenewswire.comPRELUDE THERAPEUTICS INC
NASDAQ:PRLD (2/11/2025, 3:33:41 PM)
0.9399
-0.15 (-13.77%)
a day ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
